RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 95 filers reported holding RA PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $4,381,000 | -40.1% | 91,256 | -41.4% | 0.00% | 0.0% |
| Q4 2019 | $7,313,000 | +101.5% | 155,819 | +1.6% | 0.00% | 0.0% |
| Q3 2019 | $3,629,000 | +142.7% | 153,433 | +208.6% | 0.00% | – |
| Q2 2019 | $1,495,000 | -51.7% | 49,725 | -64.0% | 0.00% | – |
| Q1 2019 | $3,093,000 | +2737.6% | 138,055 | +2212.9% | 0.00% | – |
| Q4 2018 | $109,000 | -90.3% | 5,969 | -90.4% | 0.00% | – |
| Q3 2018 | $1,128,000 | +161.1% | 62,389 | +43.6% | 0.00% | – |
| Q2 2018 | $432,000 | +1036.8% | 43,436 | +513.2% | 0.00% | – |
| Q1 2018 | $38,000 | -33.3% | 7,084 | +6.4% | 0.00% | – |
| Q4 2017 | $57,000 | +62.9% | 6,655 | +175.6% | 0.00% | – |
| Q3 2017 | $35,000 | 0.0% | 2,415 | +28.9% | 0.00% | – |
| Q2 2017 | $35,000 | +12.9% | 1,873 | +28.9% | 0.00% | – |
| Q1 2017 | $31,000 | -68.0% | 1,453 | -77.3% | 0.00% | – |
| Q4 2016 | $97,000 | – | 6,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |